Legumain在宫颈癌中的表达及相关危险因素

Expression of Legumain and its risk factors in cervical cancer

目的探讨天冬酰胺内肽酶（Legumain）在宫颈癌中的表达及Legumain高表达的相关危险因素。方法纳入行宫颈癌筛查、初筛阳性并行阴道镜下活检的患者187例,根据诊断结果分为正常组（n=84）、癌前病变组（CINⅠ~Ⅲ）（n=62）和宫颈癌组（Ⅰ~Ⅳ,FIGO分期）（n=41）,通过免疫组化检测Legumain在不同病变组织中的表达,并进一步分析影响Legumain高表达的相关危险因素。结果宫颈癌组中Legumain表达明显高于正常组和癌前病变组（P〈0.05）,但正常组与癌前病变组间表达差异无统计学意义（P〉0.05）。肿瘤组织学分型[1.483（1.258~2.950）,P=0.019]和宫颈癌FIGO分期[2.072（1.313~3.264）,P=0.011]是Legumain在宫颈癌中高表达的相关危险因素。结论Legumain在宫颈癌中呈高表达,与其组织学分型及临床分期存在相关性。

Objective To discuss the expression of Legumain and its risk factors in cervical cancer. Methods Overall 187 patients who underwent cervical cancer screening positive and parallel colposcopy biopsy were included in the study; according to the diagnostic results, the participants were divided into ： normal group, precancerous lesions group（ CIN Ⅰ ~ Ⅲ）,and cervical cancer group（Ⅰ~ Ⅳ, FIGO stage）. The expression of Legumain in different lesions were detected by immunohistochemistry, and the risk factors associated with Legumain expression were further analyzed. Results The expression level of Legumain in cervical cancer group was higher than those of normal group and precancerous lesions group（P〈0.05）, but there was no significant difference between normal group and precancerous lesions group（P〈0.05）.Increased Legumain levels were significantly correlated with tumor histological type and cervical cancer FIGO stage.Conclusion Legumain was highly expressed in cervical cancer and it is correlated with tumor histological type and cervical cancer FIGO stage; it may be one of the molecular targets for gastric cancer therapy in the future.